Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
+0.34%
SPX
+0.45%
IXIC
+0.78%
FTSE
+0.52%
N225
+0.60%
AXJO
+0.90%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks

AGEN is now overvalued and could go down -50%

Nov 02, 2024, 12:00 PM
-15.56%
What does AGEN do
Agenus, a US-based biotechnology company headquartered in Lexington, specializes in immuno-oncology therapies targeting cancer and infectious diseases, employing 389 staff. Its pipeline includes advanced antibodies and various immunotherapy classes.
Based on our analysis, Agenus Inc. has received an overvalued rating of 1 out of 5 stars from Cashu, driven by several key financial ratios that suggest underperformance compared to its sector. The Price-to-Book (PB) Ratio for Agenus stands at an alarming 24.02, far exceeding the sector average of 2.70. This ratio indicates that investors are paying a significantly higher price for each dollar of net assets, revealing potential overvaluation. Additionally, Agenus has a Net Profit Margin of -157.22, while the sector average is -138.62. A negative profit margin indicates that the company is not generating profits relative to its revenues, which could raise concerns about its operational efficiency and long-term viability. The company's Return on Equity (ROE) is reported at -69.47, compared to the sector’s -74.44. This negative figure suggests that Agenus is not effectively using shareholders’ equity to generate profits, which could deter potential investors looking for strong management of equity. Furthermore, Agenus has a Return on Assets (ROA) Ratio of -78.29, against a sector average of -47.67. This significant negative value indicates that the company is struggling to convert its assets into profitable returns, which is a critical metric for assessing operational performance. Lastly, Agenus does not offer any dividends, with a Dividend Yield of 0.00, contrasted with the sector average of 0.26. This may indicate a lack of cash flow to return to shareholders, further emphasizing the company's financial challenges. This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued

More Signals

Feature in Progress
This section is under development. Check back soon for updates!
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.